Agios Reports Business Highlights and Second Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/22/2026

6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Goldman Sachs Downgrades Agios Pharma (AGIO) to Sell

July 30, 2021 6:55 AM EDT

Goldman Sachs analyst Salveen Richter downgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Sell with a price target of $39.00 (from $58.00).

The analyst comments "We downgrade AGIO from Neutral to Sell and lower our 12-month PT to $39 from $58. AGIO's late-stage clinical pipeline... More

July 29, 2021 7:05 AM EDT

Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.41), in-line with the analyst estimate of ($1.41).

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

... More